Multi-Reference Invalidity Search: Hemangioma Patent

PROBLEM STATEMENT

The Client's Challenge

A client requested an invalidity search for a US patent claiming a method of treating hemangioma using a beta-blocker, particularly propranolol or a pharmaceutically acceptable salt, subject to a daily dosage limit of 5 mg/kg of the patient’s body weight.

The central challenge was not simply to identify publications mentioning propranolol or hemangioma independently. It was to determine whether earlier disclosures addressed the relevant claimed features with sufficient technical specificity to support a meaningful patent validity challenge.

The investigation focused on three principal technical features:

- Treatment of hemangioma, particularly capillary or infantile capillary hemangioma.
- Administration of a beta-blocker, specifically propranolol or a pharmaceutically acceptable salt.
- A daily dosage not exceeding 5 mg/kg of body weight.

CLIENT’S OBJECTIVE

Identify relevant patent and non-patent literature published or otherwise available before the applicable priority date. Assess whether multiple references could collectively support a reasoned obviousness challenge.

Account for relevant disclosures already considered during patent prosecution and the exclusions defined for the investigation.

Traditional Prior Art Search Approach

The investigation initially followed a traditional prior art search methodology commonly used in pharmaceutical patent invalidation projects. The search focused on identifying relevant disclosures across:

Conventional Investigation Strategy

Patent databases

Pharmaceutical and biomedical literature

Chemical structure and beta-blocker analog searches

Patent classification and assignee-based searches

The investigation identified several references addressing beta-blocker therapy, propranolol-based treatment of hemangioma, and dosage-related disclosures. However, these teachings were distributed across different references and therapeutic contexts and no single reference directly addressed the complete combination of claimed features.

Traditional Prior Art Search Workflow

Patent and Prosecution Review

Review granted claims and patent specification.
Examine office actions and examiner citations.
Analyze claim amendments and applicant arguments.

Keyword and Synonym Search

Identify disease and drug synonyms.
Combine keywords using Boolean operators.
Search propranolol and beta-blocker terminology.

Classification and Assignee Search

Identify relevant IPC, CPC, US and F-term classes.
Search major assignees and inventors.
Combine keywords with classifications and assignees.

Chemical Structure and Analog Search

Search beta-blocker analogs using STN.
Perform exact and substructure searches.
Identify structurally related compounds.

Scientific Literature Search

Search PubMed, Google Scholar and ScienceDirect.
Review pharmaceutical publications and research papers.
Examine relevant drug-related disclosures.

Citation Analysis and Prior Art Mapping

Conduct backward citation and similarity searches.
Map references against key claim features.
Identify missing elements and overlapping disclosures.

Outcome: Identify relevant pharmaceutical prior art and evaluate whether the individual disclosures or their combination could support a challenge to the claimed treatment method.

While conventional searching identified relevant disclosures relating to beta-blockers and hemangioma treatment, no single reference directly addressed the complete combination of the principal claim features.

Limitations of Traditional Approaches

Relevant disclosures were distributed across multiple patent publications and scientific sources.
Differences in disease terminology and drug synonyms complicated comprehensive retrieval.
Chemical structure searches identified related compounds but did not independently establish the claimed therapeutic use.
Dosage disclosures appeared in different clinical contexts and required careful technical comparison.
Translated non-US patent publications required contextual interpretation of the relevant technical teachings.
Multiple references were required to assess the relationship between the claimed treatment, active agent, and dosage limitation.

As a result, relying exclusively on the search for a single directly matching document risked overlooking a potentially relevant combination of pharmaceutical disclosures that warranted further investigation.

Start a Conversation →

Wissen’s Out-of-the-Box Approach

From Conventional Prior-Art Searching to Multi-Reference Analysis

Recognizing the limitations, the strategy evolved beyond conventional keyword-based searching to a broader, claim-focused investigation.
The objective was to identify related disclosures that could collectively support a potential challenge to the patent’s inventiveness. The investigation expanded to include:

Chemical analog and structure-based searching
Citation and similar-document analysis
Cross-jurisdictional patent searching
Claim-feature mapping

Identifying Relevant Prior Art

The investigation identified three references as particularly relevant to the claimed treatment method.
By comparing these disclosures against the key claim features, the investigation established a structured basis for evaluating a potential obviousness challenge.

Our Methodology

Traditional Search Limitations

No single reference disclosed all claimed features.
Relevant disclosures spanned different therapeutic contexts.
Terminology and translations complicated claim mapping.
Key literature had already appeared in prosecution records.

Comprehensive Prior-Art Search

Review granted claims and prosecution history.
Search keywords, synonyms, and classifications.
Combine searches with assignees and inventors.
Conduct citation and similarity searches.

Chemical Structure and Analog Search

Search beta-blocker analogs using STN.
Run exact and substructure searches.
Explore propranolol synonyms and chemical identifiers.
Screen structurally related compounds.

Multi-Database Patent and Literature Analysis

Search patent and national databases.
Review scientific literature and clinical publications.
Explore chemical and regulatory resources.
Analyze translated non-US patent documents.

Three-Reference Claim Mapping

US’319: Beta-blockers for hemangioma.
WO’319: Propranolol for capillary hemangioma.
WO’234: Dosage disclosure in another clinical context.
Compare overlapping features and claim limitations.

Evidence Assessment and Invalidity Strategy

Map disclosures against granted claims.
Verify publication dates and prior-art status.
Apply the project’s exclusion criteria.
Assess potential obviousness arguments.

Prior-Art Search Methodology

The investigation involved a comprehensive, multi-database search to identify prior-art disclosures.

The investigation identified three relevant prior-art references addressing overlapping features of the claimed invention.

US’319 disclosed beta-blockers for hemangioma treatment, WO’319 discussed propranolol for capillary or infantile capillary hemangioma, and WO’234 disclosed a dosage of 5 mg/kg per day in a different therapeutic context.

Evidence Collection & Validation

To assess the relevance of the identified prior art, multiple patent and non-patent information sources were examined and compared against the key features of the subject patent, including:

Patent publications

Scientific literature and technical disclosures

Patent prosecution records

Chemical information resources

The resulting evidence framework provided a basis for evaluating a potential obviousness challenge while recognizing that the legal significance of the combined references depends on their verified disclosures, applicable prior-art dates and the rationale for combining their teachings.

Technical Challenges Addressed Through Pharmaceutical Prior-Art Analysis

Challenge 1: Identifying Prior Art Covering the Claimed Combination of Hemangioma Treatment, Propranolol and Dosage

A key challenge involved identifying earlier disclosures that addressed the principal features of the subject patent: treatment of capillary or infantile capillary hemangioma, administration of a beta-blocker specifically propranolol or a pharmaceutically acceptable salt, and a daily dosage not exceeding 5 mg/kg of body weight. Although relevant pharmaceutical literature was identified, no single reference directly addressed the complete combination of these features.

Solution

A focused, multi-strategy prior-art investigation examined patent publications, scientific literature, chemical information resources, and related disclosures. Keyword and classification searches were supplemented by chemical analog searches, citation analysis, and detailed examination of the patent’s prosecution history.

The analysis revealed:

US’319: Disclosed the use of beta-blockers in the treatment of hemangioma.
WO’319: Specifically discussed propranolol as a beta-blocker for capillary or infantile capillary hemangioma.
WO’234: Described administration of a beta-blocker-containing medicament at a dosage of 5 mg/kg per day in a different clinical context involving neuropathic pain associated with enchondromatosis and multiple cavernous hemangiomas.

These findings established a structured basis for comparing the therapeutic indication, active agent and dosage limitation across the identified references. While the disclosures collectively supported further assessment of a potential obviousness challenge, the combination did not, by itself, establish anticipation or conclusively demonstrate invalidity.

Hemangioma Drug challenge and solution image

Challenge 2: Correlating Disclosures Across Different Therapeutic Contexts and Patent Jurisdictions

Another important challenge involved determining whether disclosures from different clinical contexts could meaningfully inform the assessment of the claimed hemangioma treatment method. The dosage disclosure in WO’234 related to a different therapeutic context while relevant information from non-US patent publications also required interpretation through translated text. Establishing technical relevance therefore required more than matching drug names or numerical dosage values.

Solution

The investigation examined each reference in its technical context and mapped its disclosures against the principal claim features. Translated patent documents were reviewed alongside available bibliographic information and the surrounding technical disclosure to assess their relevance to the subject patent.

The analysis focused on:

The therapeutic indication disclosed in each reference.
The beta-blocker or propranolol-specific teaching.
The disclosed dosage and its clinical context.
Differences between the individual disclosures and the claimed treatment method.

The findings strengthened the technical foundation for a potential multi-reference obviousness argument and provided a clearer framework for subsequent claim mapping and legal review.

Results & Business Impact

The final investigation identified three related prior-art references that addressed key features of the subject patent through a structured, multi-reference analysis. Although no single reference directly disclosed the complete claimed combination, the findings established a basis for evaluating a potential obviousness challenge.

Key Outcomes

Identification of three related prior-art references addressing key features of the claimed hemangioma treatment method.
Mapping of disclosures concerning beta-blocker therapy, propranolol use for capillary or infantile hemangioma, and a dosage of 5 mg/kg per day.
Expansion of the investigation through chemical analog searches, classification-based queries, citation analysis, and non-US patent publications.
Development of a structured, multi-reference evidence base for evaluating a potential obviousness challenge.
Identification of the technical differences and evidentiary gaps requiring further claim-level and legal assessment.

Strategic Business Impact

By expanding the investigation beyond a single-reference search and incorporating chemical analog analysis, citation searching, and cross-reference claim mapping, the investigation provided:

A broader assessment of relevant pharmaceutical prior art.
A structured basis for evaluating a potential obviousness challenge.
Improved visibility into overlaps and gaps across therapeutic, drug-specific and dosage disclosures.
A focused foundation for further legal review and claim-level analysis.
Better-informed decision-making regarding the potential strength of the patent invalidity position.

The investigation demonstrated how combining multiple search methodologies with systematic analysis of related pharmaceutical disclosures can uncover potential invalidity arguments that may remain unidentified through conventional keyword searching alone.

Conclusion & Implications

This case study highlights the importance of adopting a comprehensive and claim-focused approach to pharmaceutical patent invalidity investigations.
Traditional patent and literature searches remain valuable for identifying relevant disclosures; however, pharmaceutical patents may combine established drug classes, specific therapeutic indications and dosage limitations that are addressed separately across different references.
By expanding the investigation to include chemical analog searching, cross-jurisdictional patent analysis, and structured comparison of three related prior-art references, the project identified evidence relevant to challenging the claimed hemangioma treatment method.
Ultimately, the investigation demonstrated how a multi-reference analysis can strengthen the basis for evaluating a potential obviousness challenge while maintaining a clear distinction between overlapping technical disclosures and legally established invalidity.

What Happens When Three Prior-Art References Challenge a Hemangioma Drug Patent?

The Client's Challenge

Traditional Prior Art Search Approach

Conventional Investigation Strategy

Traditional Prior Art Search Workflow

Patent and Prosecution Review

Keyword and Synonym Search

Classification and Assignee Search

Chemical Structure and Analog Search

Scientific Literature Search

Citation Analysis and Prior Art Mapping

Wissen’s Out-of-the-Box Approach

Identifying Relevant Prior Art

Our Methodology

Prior-Art Search Methodology

Evidence Collection & Validation

Technical Challenges Addressed Through Pharmaceutical Prior-Art Analysis

Results & Business Impact

Key Outcomes

Conclusion & Implications